Wnt family member 5A
Senast uppdaterad 18 aug 2020
Uppfyller patientens redaktionella riktlinjer
- Ladda nerLadda ner
- Dela
- Language
- Diskussion
- Ask Patient
- Ljudversion
- Lägg till i föredragna källor på Google
Den WNT5A gene is part of a large family of WNT genes, which play critical roles in development starting before birth. These genes provide instructions for making proteins that participate in chemical signaling pathways in the body. Wnt signaling controls the activity of certain genes and regulates the interactions between cells during embryonic development.
Normal function
Den WNT5A gene is part of a large family of WNT genes, which play critical roles in development starting before birth. These genes provide instructions for making proteins that participate in chemical signaling pathways in the body. Wnt signaling controls the activity of certain genes and regulates the interactions between cells during embryonic development.
The protein produced from the WNT5A gene is part of chemical signaling pathways that control the movement of cells (cell migration) and attachment of cells to one another (cell adhesion) during early development. Studies suggest that the WNT5A protein plays important roles in the normal development of many parts of the body, including the brain, skeleton, blood cells, and fatty (adipose) tissue.
Conditions referring to this gene or chromosome
Other names
hWNT5A
wingless-type MMTV integration site family member 5A
wingless-type MMTV integration site family, member 5A
WNT-5A protein
Related patient information and medicines

Patient information leaflet
Huntingtons sjukdom
Huntington's disease is caused by a defective gene that you inherit from your parents. Huntingtons sjukdom is an autosomal dominant condition, meaning you can inherit the disease from just one of your parents. If one of your parents has a faulty copy of the gene, there is a 50:50 chance that each child they have will inherit the faulty gene. .

Patient information leaflet
Polycystisk njursjukdom
Non-hereditary polycystic kidney disease In about 1 in 10 people who develop polycystic kidney disease, the faulty gene is a new mutation in the affected person. Although people with PKD often develop kidney failure (end-stage kidney disease) between ages 55 to 65 years, some people with PKD h... Note : the rest of this leaflet is about ADPKD. Who.

Patient information leaflet
Marfans syndrom
Marfan syndrome can affect different people in different ways. Some people have mild symptoms; other people have more severe symptoms. You may have a history of Marfan syndrome in your family. If you have Marfan syndrome, you have a 50:50 chance of pa... It is possible but rare to have this sign without Marfan syndrome. Marfan syndrome wrist sign.

Patient information leaflet
Dystoni
Seco... It is not caused by your genetic make-up. Some neurological conditions can cause dystonia such as: Parkinson's disease Parkinson's disease. Stroke Stroke. Wilson's disease Wilson's disease. Huntington's disease Huntington's disease. When it occurs in children it is nearly always because of cerebral palsy Cerebral palsy. Some medications.

Patient information leaflet
Retinoblastom
Retinoblastom is an uncommon cancer of the eye which occurs in children under the age of 5. This leaflet describes retinoblastoma. It discusses the symptoms and signs of retinoblastoma and the management options children with retinoblastoma may be offered. Retinoblastoma is a tumour which usually affects children aged under 5. Siblings o... See.

Patient information leaflet
Duchennes muskeldystrofi
Symptoms are mild at first but increase as the child becomes older. The name Duchenne comes from the doctor who first studied this condition. How common is Duchenne muscular dystrophy. About 1 in 3,500 boys in the UK are born with DMD. There are other types of muscular dystrophy too, which are rarer. See the separate leaflet called Muscular.
Vidare läsning och referenser
- Wnt family member 5A; MedlinePlus, National Library of Medicine.
- Kikuchi A, Yamamoto H, Sato A, Matsumoto S. Wnt5a: its signalling, functions and implication in diseases. Acta Physiol (Oxf). 2012 Jan;204(1):17-33. doi: 10.1111/j.1748-1716.2011.02294.x. Epub 2011 Apr 22.
- Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol. 2006 Apr;4(4):e115. doi: 10.1371/journal.pbio.0040115. Epub 2006 Apr 4.
- Nishita M, Enomoto M, Yamagata K, Minami Y. Cell/tissue-tropic functions of Wnt5a signaling in normal and cancer cells. Trends Cell Biol. 2010 Jun;20(6):346-54. doi: 10.1016/j.tcb.2010.03.001. Epub 2010 Mar 30.
- Person AD, Beiraghi S, Sieben CM, Hermanson S, Neumann AN, Robu ME, Schleiffarth JR, Billington CJ Jr, van Bokhoven H, Hoogeboom JM, Mazzeu JF, Petryk A, Schimmenti LA, Brunner HG, Ekker SC, Lohr JL. WNT5A mutations in patients with autosomal dominant Robinow syndrome. Dev Dyn. 2010 Jan;239(1):327-37. doi: 10.1002/dvdy.22156.
- Roifman M, Marcelis CL, Paton T, Marshall C, Silver R, Lohr JL, Yntema HG, Venselaar H, Kayserili H, van Bon B, Seaward G; FORGE Canada Consortium; Brunner HG, Chitayat D. De novo WNT5A-associated autosomal dominant Robinow syndrome suggests specificity of genotype and phenotype. Clin Genet. 2015;87(1):34-41. doi: 10.1111/cge.12401. Epub 2014 May 24.
- White JJ, Mazzeu JF, Coban-Akdemir Z, Bayram Y, Bahrambeigi V, Hoischen A, van Bon BWM, Gezdirici A, Gulec EY, Ramond F, Touraine R, Thevenon J, Shinawi M, Beaver E, Heeley J, Hoover-Fong J, Durmaz CD, Karabulut HG, Marzioglu-Ozdemir E, Cayir A, Duz MB, Seven M, Price S, Ferreira BM, Vianna-Morgante AM, Ellard S, Parrish A, Stals K, Flores-Daboub J, Jhangiani SN, Gibbs RA; Baylor-Hopkins Center for Mendelian Genomics; Brunner HG, Sutton VR, Lupski JR, Carvalho CMB. WNT Signaling Perturbations Underlie the Genetic Heterogeneity of Robinow Syndrome. Am J Hum Genet. 2018 Jan 4;102(1):27-43. doi: 10.1016/j.ajhg.2017.10.002. Epub 2017 Dec 21.
Artikelhistorik
Artikeln finns också på Engelska, Tyska, Spanska, Franska, Italienska, Portugisiska, Hindi, Hebreiska, Arabiska, och Svenska.
18 aug 2020 | Senaste versionen
1 Feb 2018 | Ursprungligen publicerad
Dela dina tankar eller erfarenheter med andra i vår patientgemenskaper.
Anmäl dig till Patientens nyhetsbrev
Din veckovisa dos av tydliga, pålitliga hälsoråd - skrivna för att hjälpa dig känna dig informerad, självsäker och i kontroll.
Genom att prenumerera accepterar du våra Sekretesspolicy. Du kan avsluta prenumerationen när som helst. Vi säljer aldrig dina uppgifter.

